192 related articles for article (PubMed ID: 12446918)
1. Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells.
Kontogeorgos G; Scheithauer BW; Kovacs K; Horvath E; Melmed S
Endocr Pathol; 2002; 13(3):197-206. PubMed ID: 12446918
[TBL] [Abstract][Full Text] [Related]
2. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
[TBL] [Abstract][Full Text] [Related]
3. [Tumors of the adrenal medulla and the paraganglia].
Klöppel G
Pathologe; 2003 Jul; 24(4):280-6. PubMed ID: 14513275
[TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis of pheochromocytomas and paragangliomas.
McNichol AM
Endocr Pathol; 2001; 12(4):407-15. PubMed ID: 11914474
[TBL] [Abstract][Full Text] [Related]
5. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
6. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations.
Oudijk L; Neuhofer CM; Lichtenauer UD; Papathomas TG; Korpershoek E; Stoop H; Oosterhuis JW; Smid M; Restuccia DF; Robledo M; de Cubas AA; Mannelli M; Gimenez-Roqueplo AP; Dinjens WN; Beuschlein F; de Krijger RR
Eur J Endocrinol; 2015 Jul; 173(1):43-52. PubMed ID: 25916394
[TBL] [Abstract][Full Text] [Related]
8. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas.
Unger P; Hoffman K; Pertsemlidis D; Thung S; Wolfe D; Kaneko M
Arch Pathol Lab Med; 1991 May; 115(5):484-7. PubMed ID: 1673596
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of S-100 protein in sustentacular cells of phaeochromocytomas and paragangliomas.
Schroder HD; Johannsen L
Histopathology; 1986 Oct; 10(10):1023-33. PubMed ID: 3536711
[TBL] [Abstract][Full Text] [Related]
10. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 producing pheochromocytoma/paraganglioma: case series from a tertiary referral centre for pheochromocytomas and paragangliomas.
Meijs AC; Schroijen MA; Snel M; Corssmit EPM
J Endocrinol Invest; 2021 Oct; 44(10):2253-2259. PubMed ID: 33715142
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Staining for SOX10 and SDHB in SDH-Deficient Paragangliomas Indicates that Sustentacular Cells Are Not Neoplastic.
Powers JF; Tischler AS
Endocr Pathol; 2020 Sep; 31(3):307-309. PubMed ID: 32562155
[No Abstract] [Full Text] [Related]
13. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.
Favier J; Igaz P; Burnichon N; Amar L; Libé R; Badoual C; Tissier F; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP
Endocr Pathol; 2012 Mar; 23(1):34-42. PubMed ID: 22183643
[TBL] [Abstract][Full Text] [Related]
14. Morphologic Clues to Succinate Dehydrogenase (SDH) Deficiency in Pheochromocytomas and Paragangliomas.
Turchini J; Gill AJ
Am J Surg Pathol; 2020 Mar; 44(3):422-424. PubMed ID: 31789631
[No Abstract] [Full Text] [Related]
15. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
16. N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.
Leijon H; Kaprio T; Heiskanen A; Satomaa T; Hiltunen JO; Miettinen MM; Arola J; Haglund C
J Clin Endocrinol Metab; 2017 Nov; 102(11):3990-4000. PubMed ID: 28938401
[TBL] [Abstract][Full Text] [Related]
17. Class III beta-tubulin isotype (beta III) in the adrenal medulla: II. Localization in primary human pheochromocytomas.
Karkavelas G; Katsetos CD; Geddes JF; Herman MM; Vinores SA; Cooper HS; Provencio J; Frankfurter A
Anat Rec; 1998 Mar; 250(3):344-50. PubMed ID: 9517851
[TBL] [Abstract][Full Text] [Related]
18. Paraganglioma of the Organ of Zuckerkandl.
Huan L; Jetly R; Kandil E
J La State Med Soc; 2012; 164(1):26-30. PubMed ID: 22533110
[TBL] [Abstract][Full Text] [Related]
19. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
20. Functional tumors of the organ of Zuckerkandl.
Glenn F; Gray GF
Ann Surg; 1976 May; 183(5):578-86. PubMed ID: 179483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
